The cost of Wegovy: $1.1M to prevent one major cardiovascular event, Airfinity says
The impact of Novo Nordisk’s GLP-1 semaglutide on cardiovascular health was received with great fanfare earlier this month, with the Danish pharma touting a 20% reduction in major adverse cardiovascular events (MACE) by 20% in obese or overweight patients without diabetes in its vast SELECT trial.
But a new analysis from disease forecasting company Airfinity says that the price tag to actually prevent one heart attack, stroke or cardiovascular death could be $1.1 million, even after a 65% rebate on the list price.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
